Citigroup Maintains Buy on Veradermics, Raises Price Target to $160

Benzinga Newsdesk www.benzinga.com Positive 70.0%

Neg 0% Neu 0% Pos 70%

Citigroup analyst Geoff Meacham maintains Veradermics (NYSE:MANE) with a Buy and raises the price target from $135 to $160.